loader
Please Wait
Applying Filters...

Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    List of Drug Master Files (DMF) for 13101 Active Pharmaceutical Ingredient (API) submitted to the U.S. FDA. Original Data : FDA Website

    Client Virtual Booth
    Menu

    Amsa Spa

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Aspen API. More than just an API.

    Left Arrow
    Right Arrow
    Filters Filter
    Cross PopUp
    FILTER :

    filter

    01 Amsa Spa (1)

    filter

    01 GLIPIZIDE (1)

    filter

    01 Italy (1)

    filter

    01 Active (1)

    filter

    01 Complete (1)

    ListList of Suppliers
    refresh Reset Filter
    refresh Reset Filter
    product-page Supplier Virtual Booth
    price-trend Ask Us

    AMSA SPA

    Contact Supplier
    • FDA
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
    Post an Enquiry Post an Enquiry
    Flag Italy
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    GLIPIZIDE

    PDF Supplier PDF
    URL Supplier Web Content
    13101
    Active
    1998-07-30
    Complete
    2014-03-21
    2013-09-23
    II
    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content

    Looking for Drug Master Files (DMF) for 13101 of Amsa Spa

    Looking for Drug Master Files (DMF) for 13101 of Amsa Spa 1

    20

    Amsa Spa, based in Italy, is a pharmaceutical company that stands out with its certifications from FDA.

    One of their notable products is GLIPIZIDE, with a corresponding US DMF Number 13101.

    Remarkably, this DMF maintains an Active status since its submission on July 30, 1998, highlighting commitment to regulatory compliance.

    Their GDUFA DMF Review was successfully complete, with a review date of March 21, 2014, and payment made on September 23, 2013, indicating their dedication to facilitating drug approvals, Categorized as Type II

    Post Enquiry
    POST ENQUIRY